Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 15/20 | 0.66 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.63 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.63 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.63 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.63 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.62 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | FLT3 | P36888 | 4/20 | 0.58 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13946065 | 0.85 | RAF1 (0.66) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13946063 | 0.83 | RAF1 (0.64) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13946067 | 0.81 | RAF1 (0.82) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13945909 | 0.81 | KDR (0.50) | RAF1KDRFLT3CSF1RPDGFRA | |
| SCHEMBL13946023 | 0.79 | RAF1 (0.44) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL667817 | 0.79 | RAF1 (0.80) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13946028 | 0.79 | RAF1 (0.50) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13946078 | 0.78 | KDR (0.45) | KDRCSF1RPDGFRA | |
| SCHEMBL668361 | 0.78 | RAF1 (0.82) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5573447 | 0.78 | RAF1 (1.00) | RAF1MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | KINAGEN, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | KINAGEN, INC. (US) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | CYP11B2, NOS2, HMOX2 | RAF1 3755/4885MAPK14 1679/4885MAPK13 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.